FDA Alert: Zerbaxa (ceftolozane and tazobactam): Drug Safety Communication – FDA Cautions about Dose Confusion and Medication Errors

To my pharmacist and doctor friends – you might want to to take a look at this article. The FDA studied 7 cases and found that confusion was resulting because the strength of individual ingredients displayed on Zerbaxa’s vial labels and carton labeling was different. Some of the cases studied showed that this was resulting in a 50% over-administration of the drug. 

FDA Alert: Zerbaxa (ceftolozane and tazobactam): Drug Safety Communication – FDA Cautions about Dose Confusion and Medication Errors.

Advertisements